ELUCIREM (gadopiclenol) by Guerbet is (macrocyclic non-ionic complex of gadolinium) that develops a magnetic moment when placed in a magnetic field. Approved for including term neonates, for use with magnetic resonance imaging (mri) to detect, visualize lesions with abnormal vascularity in: the central nervous system (brain and 7 more indications. First approved in 2022.
Drug data last refreshed 7h ago · AI intelligence enriched 6d ago
ELUCIREM (gadopiclenol) is a macrocyclic gadolinium-based contrast agent administered intravenously to enhance MRI imaging. It develops magnetic properties in the MRI field to increase signal intensity and visualize lesions with abnormal vascularity across the CNS, head, neck, thorax, abdomen, pelvis, and musculoskeletal system. The agent is approved for use in patients including term neonates.
Early-stage peak lifecycle product with no documented competitive pressure, suggesting potential for market expansion and team growth.
(macrocyclic non-ionic complex of gadolinium) that develops a magnetic moment when placed in a magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in signal intensity (brightness) of tissues.
Worked on ELUCIREM at Guerbet? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease
MRI Gadopiclenol Enhanced Imaging of CNS Tumors
Gadopiclenol vs Gadoxetate MRI for Liver Lesions
Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics
Gadopiclenol in Contrast Enhanced MRI of the Prostate
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moELUCIREM is a newly approved (2022) diagnostic agent in peak lifecycle with 13.6 years of patent protection, creating growth-phase opportunities in commercial and medical teams. Working on this product offers exposure to contrast media market dynamics and the diagnostic imaging segment, with career security through the mid-2030s.